Regeneron Pharmaceuticals' Tax Provisions rose 39282.18% to $199.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $725.8 million, marking a year-over-year increase of 9760.41%. This contributed to the annual value of $725.8 million for FY2025, which is 9760.41% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Tax Provisions stood at $199.1 million for Q4 2025, which was up 39282.18% from $303.3 million recorded in Q3 2025.
Regeneron Pharmaceuticals' Tax Provisions' 5-year high stood at $653.9 million during Q2 2021, with a 5-year trough of -$21.3 million in Q1 2024.
Over the past 5 years, Regeneron Pharmaceuticals' median Tax Provisions value was $127.4 million (recorded in 2022), while the average stood at $155.5 million.
Per our database at Business Quant, Regeneron Pharmaceuticals' Tax Provisions skyrocketed by 292731.48% in 2021 and then crashed by 15298.51% in 2024.
Regeneron Pharmaceuticals' Tax Provisions (Quarter) stood at $274.4 million in 2021, then plummeted by 53.5% to $127.6 million in 2022, then plummeted by 109.4% to -$12.0 million in 2023, then skyrocketed by 436.67% to $40.4 million in 2024, then soared by 392.82% to $199.1 million in 2025.
Its last three reported values are $199.1 million in Q4 2025, $303.3 million for Q3 2025, and $127.1 million during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value